Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CDR132L SC vs IV in Healthy Participants
NCT07656454Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CDR132L in heart failure (HF) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from 0 hours to tz at 840 hours. Started Jun 2026; status: recruiting.
02
Drugs
CDR132L
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07656454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656454.